|
|
???tair.name??? >
???browser.page.title.author???
|
"tseng k c"???jsp.browse.items-by-author.description???
Showing items 76-85 of 144 (15 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-03-09T01:47:43Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Hsu C.-S.; Lin H.H.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:38Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Lin H.H.; Wang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:33Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:32Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 國立成功大學 |
2021 |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang, C.-F.;Kuo, H.-T.;Chang, T.-S.;Lo, C.-C.;Hung, C.-H.;Huang, C.-W.;Chong, L.-W.;Cheng, P.-N.;Yeh, M.-L.;Peng, C.-Y.;Cheng, Cheng C.-Y.;Huang, J.-F.;Bair, M.-J.;Lin, C.-L.;Yang, C.-C.;Wang, S.-J.;Hsieh, T.-Y.;Lee, T.-H.;Lee, P.-L.;Wu, Wu W.-C.;Lin, C.-L.;Su, W.-W.;Yang, S.-S.;Wang, C.-C.;Hu, J.-T.;Mo, L.-R.;Chen, Chen C.-T.;Huang, Y.-H.;Chang, Chang C.-C.;Huang, C.-S.;Chen, G.-Y.;Kao, C.-N.;Tai, C.-M.;Liu, C.-J.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Kao, J.-H.;Lin, H.-C.;Chuang, W.-L.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh, M.-L.;Hung, C.-H.;Tseng, K.-C.;Lai, H.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Tsai, P.-C.;Peng, C.-Y.;Liu, C.-J.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh, M.-H.;Bair, M.-J.;Tsai, P.-C.;Tseng, K.-C.;Lo, C.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Hung, C.-H.;Lai, H.-C.;Peng, C.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Tai, C.-M.;Lin, C.-W.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Yeh, M.-L.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Yu, M.-L.;Chuang, W.-L.;investigators, T-COACH |
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng, P.-N.;Chen, Chen C.-Y.;Yu, M.-L.;Lin, C.-C.;Lin, C.-Y.;Peng, C.-Y.;Tseng, K.-C.;Lo, C.-C.;Tseng, I.-H.;Liu, C.-J. |
| 國立成功大學 |
2021 |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu, W.-F.;Tsai, P.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Lai, H.-C.;Kuo, H.-T.;Hung, C.-H.;Tung, S.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Lin, C.-Y.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Yu, M.-L.;Peng, C.-Y. |
Showing items 76-85 of 144 (15 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page
|
